Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
58.6M
-
Number of holders
-
207
-
Total 13F shares, excl. options
-
54.4M
-
Shares change
-
-417K
-
Total reported value, excl. options
-
$4.58B
-
Value change
-
-$33.6M
-
Put/Call ratio
-
0.59
-
Number of buys
-
112
-
Number of sells
-
-75
-
Price
-
$84.23
Significant Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) as of Q2 2018
241 filings reported holding AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock as of Q2 2018.
AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) has 207 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.4M shares
of 58.6M outstanding shares and own 92.79% of the company stock.
Largest 10 shareholders include FMR LLC (8.64M shares), WELLINGTON MANAGEMENT GROUP LLP (7.65M shares), VANGUARD GROUP INC (4.14M shares), BlackRock Inc. (3.25M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.95M shares), Capital International Investors (2.81M shares), BB BIOTECH AG (2.2M shares), Clearbridge Investments, LLC (1.51M shares), STATE STREET CORP (1.35M shares), and GOLDMAN SACHS GROUP INC (1.26M shares).
This table shows the top 207 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.